Ozempic
-
Amid ongoing global shortages of semaglutide, the active ingredient in medical sensations Ozempic and Wegovy, researchers have uncovered a way to make 10 times more of the stuff, producing a therapeutically similar version of the in-demand drug.
-
Next-gen anti-obesity drugs like injectable liraglutide, sold as Saxenda, deliver impressive results in the first 12 months. New research looks into what happens to those results once treatment stops.
-
In yet another surprise attribute of the new class of obesity drugs, scientists have found that GLP-1 receptor agonists can also subdue brain inflammation, giving them a potential ‘superpower’ in the fight against Alzheimer’s and Parkinson’s diseases.
-
New research found that patients taking the weight-loss and diabetes drug semaglutide had significantly reduced symptoms of alcohol use disorder. Larger studies are currently underway to see whether the drug is an effective treatment for addiction.
-
Research has found that signals linked to how food tastes are sent to our brains almost immediately to slow our eating pace, with the well-known stretch signals from the gut coming later, providing greater insights into how the body controls appetite.
-
Managing diabetes usually involves regular shots, but soon patients might only need injections a few times a year. Stanford has developed a hydrogel-based delivery system that slowly releases drugs over months to control diabetes and even weight.
-
The US has officially got a homegrown hero in the burgeoning global industry of effective weight-loss treatment, with the FDA approval of Lilly’s Zepbound. The company has revealed its cost, dosages, insurance subsidies and when it will be on shelves.